THE ERASE TRIAL: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
 
(6 intermediate revisions by 2 users not shown)
Line 2: Line 2:
{{High density lipoprotein}}
{{High density lipoprotein}}


{{CMG}}; {{AE}}: {{Rim}}
{{CMG}}; {{AE}} {{Rim}}


'''Click [[media:ERASE_Trial.ppt|here]] to download slides for ERASE Trial.'''
'''Click [[media:ERASE_Trial.ppt|here]] to download slides for ERASE Trial.'''
Line 19: Line 19:
|-
|-
| Style="width:30%"| '''Start Date'''||Style="width:70%"| July 2005
| Style="width:30%"| '''Start Date'''||Style="width:70%"| July 2005
|-
| '''Run-In Period'''||
|-
|-
| '''End Date'''||Not provided
| '''End Date'''||Not provided
Line 31: Line 29:
==Study Description==
==Study Description==


{| class="wikitable" border="1" style="background:WhiteSmoke" width="40%"
{| class="wikitable" border="1" style="background:WhiteSmoke" width="60%"
|-
|-
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Description'''
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Description'''
|-
|-
| Style="width:30%"|'''Study Type'''|| Style="width:70%"|
| Style="width:20%"|'''Study Type'''|| Style="width:80%"|Interventional
|-
|-
| '''Study Phase''' ||
| '''Study Phase''' ||Phase 2
|-
|-
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Design'''
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Design'''
|-
|-
| '''Allocation'''||Interventional
| '''Allocation'''||Randomized
|-
|-
| '''Endpoint'''||Safety/Efficacy Study
| '''Endpoint'''||Safety/efficacy study
|-
|-
| '''Interventional Model'''||Parallel Assignment
| '''Interventional Model'''||Parallel assignment
|-
|-
| '''Masking'''||Double-Blind
| '''Masking'''||Double-blind
|-
|-
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Details'''
| Colspan="2" style="background:Gainsboro" align="center"|'''Study Details'''
Line 53: Line 51:
| '''Primary Purpose'''||Treatment
| '''Primary Purpose'''||Treatment
|-
|-
| '''Condition'''||Acute Coronary Syndromes
| '''Condition'''||Acute coronary syndromes
|-
|-
| '''Intervention'''||Drug: rHDL
| '''Intervention'''||Drug: rHDL
Line 118: Line 116:
[[Category:HDL]]
[[Category:HDL]]
[[Category:Clinical trials]]
[[Category:Clinical trials]]
[[Category:HDLpedia]]

Latest revision as of 14:24, 21 October 2013

High Density Lipoprotein Microchapters

Home

Patient information

Overview

Historical Perspective

Classification

Physiology

Pathophysiology

Causes

Low HDL
High HDL

Epidemiology and Demographics

Screening

Natural History, Complications and Prognosis

Diagnosis

HDL Laboratory Test

Treatment

Medical Therapy

Prevention

Future or Investigational Therapies

Clinical Trials

Landmark Trials

List of All Trials

Case Studies

Case #1

THE ERASE TRIAL On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of THE ERASE TRIAL

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on THE ERASE TRIAL

CDC on THE ERASE TRIAL

THE ERASE TRIAL in the news

Blogs on THE ERASE TRIAL

Directions to Hospitals Treating High density lipoprotein

Risk calculators and risk factors for THE ERASE TRIAL

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Rim Halaby, M.D. [2]

Click here to download slides for ERASE Trial.

Official Title

Regression of Coronary Atherosclerotic Lesions After rHDL Infusions in Acute Coronary Syndrome Patients as Assessed by Intravascular Ultrasound

Objective

To study the effects of reconstituted HDL on atheromatous plaque volume as assessed by intravascular ultrasound (IVUS).[1]

CSL Limited

Timeline

Timeline
Start Date July 2005
End Date Not provided
Status Completed

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00225719.

Study Description

Study Description
Study Type Interventional
Study Phase Phase 2
Study Design
Allocation Randomized
Endpoint Safety/efficacy study
Interventional Model Parallel assignment
Masking Double-blind
Study Details
Primary Purpose Treatment
Condition Acute coronary syndromes
Intervention Drug: rHDL
Study Arms
  • 60 patients receiving placebo, defined as normal saline infusion
  • 111 patients receiving CSL-111 infusion at a dose of 40 mg/kg
  • 12 patients receiving CSL-111 infusion at a dose of 80 mg/kg

Therapy was required to take place within 2 weeks of an acute coronary syndrome. Before infusion, baseline IVUS of target coronary artery using 40-MHz catheters was performed and need to fulfill the following conditions:

  • Proximal 4 cm needed to have a reference diameter of at least 2.5 mm
  • No filling defects of thrombotic nature
  • No reduced luminal diameter by 50% or more according to angiographic estimation at baseline
  • No previous percutaneous coronary intervention (PCI)
  • Not a previous candidate for intervention at time of the baseline catheterization.

Patients received 4 weekly volume-matched infusions; but infusions can be postponed for 1 week on a maximum of 2 consecutive occasions if liver transaminases were > 1.5 times the upper normal limit.[1]

Follow-up IVUS at the same target artery segment occurred 2-3 weeks after last infusion:

  • 47 patients of placebo group had baseline and follow-up IVUS
  • 89 patients of CSL-111 40 mg/kg group had baseline and follow-up IVUS
  • 9 patients of CSL-111 80 mg/kg group had baseline and follow-up IVUS
Population Size 180

The previous information was derived from ClinicalTrials.gov on 09/19/2013 using the identification number NCT00225719.

Eligibility Criteria

Inclusion Criteria

  • Male or female 30 - 75 years of age
  • Recent acute coronary syndrome, defined as unstable angina, non-Q wave myocardial infarction, or ST elevation indicative of myocardial infarction, within the :last 14 days

Exclusion Criteria

Outcomes

Primary Outcomes

Percentage difference in volume of atheroma between follow-up and baseline on IVUS.[1]

Secondary Outcomes

Absolute change in coronary score, defined as the mean of minimal lumen diameter for all measured lesions on angiography, and change in plaque volume and characterization on IVUS.[1]

Publications

Results

After 4 weeks of infusion, plaque volume changes was not significantly different among the placebo and CSL-111 groups combined (p=0.48).[1] There was a significant change in atheroma volume in both groups when compared to baseline volume(-1.62% in placebo (p=0.07) and -3.41% in CSL-111 40 mg/kg (p<0.001), but the change was not significant when comparing different groups to each other (p=0.39).[1]

There was a significant difference in plaque characterization index on IVUS where index showed -0.0097 for CSL-111 vs. 0.0128 for placebo(p=0.01).[1] Similarly, mean differences of angiographic coronary scores were also significnat whereby mean score change was =0.039 mm for CSL-111 vs. -0.071 mm in placebo (p=0.03).[1]

The safety of CSL-111 was well-studied. Generally, CSL-111 was well tolerated with mild-moderate adverse events only with no varying rates between CSL-111 treatment and placebo groups except in rates of hypotension (13.8% vs. 7.1%, respectively).[1] Elevation in liver function tests, especially after 24 hours of infusion, were all subclinical events that later normalized with no intervention. Notably, there was also a self-limited increase in unconjugated bilirubin.[1]

Conclusion

Short-term CSL-111 infusions showed significant improvement in plaque characterization index and coronary score on angiography, but did not yield significant changes in plaque or atheroma volume.[1] Clinically, the importance of these findings is still poorly outlined.

References

  1. 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 Tardif JC, Grégoire J, L'Allier PL; et al. (2007). "Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial". JAMA : the Journal of the American Medical Association. 297 (15): 1675–82. doi:10.1001/jama.297.15.jpc70004. PMID 17387133. Unknown parameter |month= ignored (help)